Bone Marrow Transplant
|Recruiting||Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Patients with new diagnoses of non-M3 AML or high-risk MDS who present for AML-like treatment that could plausibly produce a complete remission (CR); for example intensive induction chemotherapy, low dose single agent chemotherapy, hypo-methylation agent, or a similar therapy
- Explicitly intend to establish follow-up care at one of the collaborating institutions.
- Patients of ≥18 years of age and are being treated by the adult AML service.
- Able to read and speak English.
- Willing and able to provide informed consent.
- Patients of ≤17 years of age or who are ≥18 and receive treatment under the pediatric AML service.
- Patients older than 80 years
- Patients with <6 months projected survival due to active second malignancy or other medical problem.
Other exclusion criteria may apply.
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.